OpenAI

Background

OpenAI is an American artificial intelligence research and product company, best known for the ChatGPT assistant and the GPT family of large language models. Founded in 2015, it sits outside the usual boundaries of a longevity or biotechnology company, yet it has become an important actor in the future of human enhancement for two reasons: its models are increasingly used as tools in biological and medical research, and its chief executive, Sam Altman, is a significant private investor in life-extension science. OpenAI was founded in December 2015 as a nonprofit research laboratory, with a founding group that included Sam Altman, Elon MuskPersonElon MuskEntrepreneur behind Tesla and SpaceX who co-founded the brain-computer interface company Neuralink to link the human brain with computers and keep pace with AI.Person →, Greg Brockman, and Ilya Sutskever, and a stated mission to ensure that advanced artificial intelligence benefits humanity. Musk departed the board in 2018. In 2019 the organization adopted a capped-profit structure to raise the capital needed to train large models and entered a major partnership with Microsoft, and in late 2022 it released ChatGPT, which brought generative AI to a mass audience.

AI for biology and medicine

Modern AI has become a practical instrument in the life sciences, and OpenAI's models are part of that shift. Researchers use large language models to read and summarize the scientific literature, generate and critique hypotheses, write analysis code, and reason over complex biological data, complementing the specialized systems central to AI drug discovery. The most direct link to longevity came from a collaboration with Retro BiosciencesCompanyRetro BiosciencesLongevity biotechnology company launched in 2022 and reportedly funded largely by Sam Altman, aiming to add years to human lifespan through reprogramming, autophagy, and plasma work.Company →, a company working on cellular rejuvenation. OpenAI reported building a specialized model, called GPT-4b micro, to help redesign proteins, and with Retro applied it to the Yamanaka factors, the reprogramming proteins central to epigenetic reprogramming. The teams reported that AI-designed variants of two factors substantially increased markers of cell reprogramming in laboratory tests. These results are early, company-reported, and not yet independently established, but they illustrate the ambition of applying language-model-style AI to the proteins of aging biology.

Sam Altman and longevity

Beyond OpenAI, Sam Altman has personally backed radical life extension research. He has invested a reported 180 million dollars in Retro BiosciencesCompanyRetro BiosciencesLongevity biotechnology company launched in 2022 and reportedly funded largely by Sam Altman, aiming to add years to human lifespan through reprogramming, autophagy, and plasma work.Company →, whose stated goal is to add roughly ten healthy years to human life, one of the larger individual bets in the field. Altman has also spoken favorably about the promise of ambitious biotechnology, reflecting a view that progress in AI and progress in biology may reinforce one another. This places OpenAI's leadership within a Silicon Valley current that overlaps with transhumanismTermTranshumanismA philosophical and technical movement focused on using science and engineering to expand human capacities and resilience.In glossary →, the belief that technology can and should be used to extend human capacities and lifespan. The same current runs through neighboring projects such as the brain-computer-interface company NeuralinkCompanyNeuralinkBrain-computer interface company co-founded by Elon Musk in 2016, developing the implantable N1 device and R1 surgical robot to let people control computers by thought.Company → and speculative goals like mind uploading, and through the futurism of writers such as Ray KurzweilPersonRay KurzweilAmerican inventor and futurist known for pioneering OCR and speech technology, the law of accelerating returns, and predictions of a technological singularity around 2045.Person →, even though these differ greatly in maturity and evidence.

Reception and debate

OpenAI's role in the enhancement conversation is genuinely double-edged. Optimists, including many longevity researchers, argue that faster, cheaper reasoning over biological data could compress the timeline for understanding and treating aging, and that AI-assisted protein and molecule design is already changing how experiments are planned. Critics caution against hype, noting that a language model can accelerate parts of research, but drugs still require years of laboratory and clinical testing, and impressive laboratory metrics do not equal proven therapies. There are also broader worries about safety, reliability, and the concentration of powerful AI in a few companies. For the purposes of human enhancement, the honest summary is that OpenAI supplies increasingly capable tools and its leadership supplies capital and attention, while the medical payoff remains a promise rather than a demonstrated result.

Related pages

What links here

• Elon Musk
• Retro Biosciences